Ex vivo and in vivo designs for cryopyrin-associated periodic syndromes (CAPS), type 2 diabetes, gout and non-alcoholic fatty liver disease (NAFLD) have established the efficacy of CY-09, although further research is required to materialize its full therapeutic value [134,135]. The gene discussed is NLRP3; the disease is gout.